Browsing Category
Featured Articles
FDA Approves Boehringer Ingelheim’s JASCAYD as First PDE4B Inhibitor for Idiopathic Pulmonary…
Boehringer Ingelheim has received approval from the U.S. Food and Drug Administration (FDA) for its new oral therapy, JASCAYD (nerandomilast), for the treatment of idiopathic pulmonary…
Read More...
Read More...
FDA Approves Regeneron’s Libtayo as First Adjuvant Immunotherapy for High-Risk CSCC
The U.S. Food and Drug Administration (FDA) has approved Regeneron Pharmaceuticals' Libtayo® (cemiplimab-rwlc) as the first adjuvant immunotherapy for adult patients with cutaneous…
Read More...
Read More...
Algen Biotechnologies and AstraZeneca Partner to Accelerate Immunology Drug Discovery Using AI and…
Algen Biotechnologies has entered a multi-target partnership with AstraZeneca aimed at speeding up the discovery of new therapeutic targets in immunology. The collaboration will…
Read More...
Read More...
FDA Grants Fast Track Designation to Bristol Myers Squibb’s Alzheimer’s Antibody BMS-986446
Bristol Myers Squibb announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation to BMS-986446, a promising anti-microtubule binding region-tau…
Read More...
Read More...
Pfizer Reaches Landmark Agreement with U.S. Government to Lower Drug Costs for American Patients
Pfizer has announced a historic agreement with the Trump Administration aimed at significantly reducing prescription drug prices for American patients while reinforcing the U.S.'s…
Read More...
Read More...
AstraZeneca and Daiichi Sankyo’s Enhertu Shows Strong Phase III Results in HER2-Positive Early…
AstraZeneca and Daiichi Sankyo announced positive interim results from the DESTINY-Breast05 Phase III trial, reinforcing Enhertu’s (trastuzumab deruxtecan) potential as a foundational…
Read More...
Read More...
FDA Approves TREMFYA for Pediatric Psoriasis and Psoriatic Arthritis
Johnson & Johnson has announced that the U.S. Food and Drug Administration (FDA) has approved its biologic therapy TREMFYA® (guselkumab) for use in children aged six years and older…
Read More...
Read More...
FDA Approves Inluriyo for Advanced ER+, HER2-, ESR1-Mutated Breast Cancer
The U.S. Food and Drug Administration (FDA) has approved Inluriyo (imlunestrant, 200 mg tablets), a new oral treatment from Eli Lilly and Company, for adults with estrogen…
Read More...
Read More...
FDA Grants Priority Review to AstraZeneca and Daiichi Sankyo’s Enhertu for First-Line HER2-Positive…
AstraZeneca and Daiichi Sankyo have announced that the U.S. Food and Drug Administration (FDA) has accepted their supplemental Biologics License Application (sBLA) for Enhertu…
Read More...
Read More...
Sanofi Boosts Sanofi Ventures with $625M to Accelerate Biotech and Digital Health Investments
Sanofi Ventures has received an additional $625 million multi-year capital commitment from its parent company, Sanofi, increasing its total assets under management to over $1.4 billion.…
Read More...
Read More...
Moderna Opens Cutting-Edge Manufacturing and R&D Facility in the UK
Moderna, Inc. has officially opened its Moderna Innovation and Technology Centre (MITC) at the Harwell Science and Innovation Campus in Oxfordshire, UK. This new facility will…
Read More...
Read More...
Roche’s Giredestrant Shows Significant Progression-Free Survival Benefit in Phase III ER-Positive…
Roche has announced positive results from the Phase III evERA study evaluating giredestrant combined with everolimus in patients with estrogen receptor (ER)-positive, HER2-negative,…
Read More...
Read More...
Roche to Acquire 89bio in Merger Deal, Gaining Phase 3 MASH Therapy Candidate
Roche announced that it has entered into a definitive agreement to acquire 89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company developing innovative therapies for…
Read More...
Read More...
GSK to Invest $30 Billion in U.S. R&D and Manufacturing Over Next 5 Years
GSK plc announced plans to invest $30 billion in the United States over the next five years, focusing on research and development and supply chain infrastructure. This major investment…
Read More...
Read More...
FDA Grants Breakthrough Therapy Designation to Raludotatug Deruxtecan for CDH6-Positive…
Raludotatug deruxtecan (R-DXd), a novel CDH6-targeted antibody-drug conjugate developed by Daiichi Sankyo and Merck, has received Breakthrough Therapy Designation (BTD) from the U.S.…
Read More...
Read More...
EU Approves Novo Nordisk’s Oral Semaglutide as First GLP-1 Pill to Cut Heart Risks
The European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has approved an update to the label of Novo Nordisk’s oral diabetes drug Rybelsus (oral…
Read More...
Read More...
Tzield Approved in China as First Disease-Modifying Therapy for Stage 2 Type 1 Diabetes
The Chinese National Medical Products Administration (NMPA) has approved Tzield (teplizumab) as the country’s first disease-modifying therapy for autoimmune type 1 diabetes (T1D). The…
Read More...
Read More...
CAPVAXIVE Shows Strong Immune Response in At-Risk Children and Teens
Merck, known as MSD outside the U.S. and Canada, announced positive results from its Phase 3 STRIDE-13 trial evaluating CAPVAXIVE, its 21-valent pneumococcal conjugate vaccine, in…
Read More...
Read More...
Novartis to Acquire Tourmaline Bio, Boosting Cardiovascular Pipeline with Pacibekitug for ASCVD…
Novartis announced it has agreed to acquire Tourmaline Bio, a clinical-stage biopharmaceutical company focused on developing pacibekitug, an anti-IL-6 monoclonal antibody designed to…
Read More...
Read More...
Health Canada Approves ELAHERE for Platinum-Resistant Ovarian Cancer
AbbVie announced that Health Canada has approved ELAHERE® (mirvetuximab soravtansine for injection) under the Priority Review process. ELAHERE is an antibody-drug conjugate (ADC)…
Read More...
Read More...
